Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.
Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses next steps with immunotherapy in the treatment of patients with advanced renal cell carcinoma.
Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how to choose between combination therapies in the treatment of patients with melanoma.
Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses targeted therapy options for patients with uterine sarcomas.
Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular diagnostics in gastrointestinal (GI) cancers.
Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.
Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses frontline tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC).
Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the synergy between abiraterone acetate (Zytiga) and androgen deprivation therapy (ADT) in prostate cancer.
Andrea V. Barrio, MD, FACS, breast surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with HER2-positive breast cancer.
Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the challenges associated with implementing liquid biopsies in pediatric sarcoma.
Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses a study analyzing effective combinations with regorafenib for the treatment of pediatric rhabdomyosarcomas.
Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, discusses the impact of the recently published SPARTAN and PROSPER trials in nonmetastatic castration-resistant prostate cancer.
James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses the role of surgery in patients with high-risk prostate cancer.
Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.
Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia (CHOP), discusses frontline therapy for pediatric patients with Ph-like acute lymphoblastic leukemia (ALL).
Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).
Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses EGFR-targeted therapies in non–small cell lung cancer.
William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.
Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses drug development in acute myeloid leukemia (AML).
P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.
Natasha Leighl, MD, medical oncologist, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, discusses binimetinib (Mektovi) in KRAS-mutated non–small cell lung cancer.
Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the next steps of the St. Jude Lifetime Cohort Study.
Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses surgical approaches in breast cancer.
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses eliminating financial toxicity in oncology.
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.
Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer
Keith Kerr, BSc, MB, ChB, consultant pathologist, University of Aberdeen, Aberdeen, Scotland, discusses common misconceptions with molecular profiling in lung cancer.
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.
Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the role of smoking status in the diagnosis of bladder cancer.
